Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTION, EMULSIONGeneric

APREPITANT

APREPITANT

Standard Dose
130MG/18ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview APREPITANT is listed in Drugs@FDA under application 216976 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient APREPITANT Form and strength INJECTION, EMULSION - 130MG/18ML Sponsor MYLAN PHARMACEUTICALS INC Submission history Latest submission status date: 2025-11-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview APREPITANT is listed in Drugs@FDA under application 216976 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient APREPITANT Form and strength INJECTION, EMULSION - 130MG/18ML Sponsor MYLAN PHARMACEUTICALS INC Submission history Latest submission status date: 2025-11-17 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.